Inactivated polio vaccine

ApprovedVaccine

GSK

Inactivated polio vaccine is one of 21 biologic programs targeting Influenza. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaApproved

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Inactivated polio vaccine

GSK

Approved

4 2

Fluzone

Sanofi

Preclinical

16 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Avigan

AAppili Therapeutics Inc.

Preclinical

6 5

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 6

COMIRNATY

Pfizer

Preclinical

1 7

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

Diphtheria-Tetanus-Acellular Pertussis Vaccine

CanSino Biologics Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza4 trials

Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya

Withdrawn·CCenters for Disease Control and Prevention·Phase 2/3·NCT01810731

Inactivated Influenza Vaccine Effectiveness in Tropical Africa

Completed·PPATH·Phase 4·NCT00893906·10,000 enrolled

An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh

Active, not recruiting·UUniversity of Bergen·Phase 4·NCT04998344·3,800 enrolled

Show 1 more trial

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Completed·—·Phase 4·NCT00934245·4,598 enrolled

Immunogenicity2 trials

Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

Completed·CChina National Biotec Group Company Limited·Phase 4·NCT04051736·360 enrolled

Immunogenicity of Inactivated and Live Polio Vaccines

Completed·CCenters for Disease Control and Prevention·Phase 3·NCT01813604·1,206 enrolled

Immune Response1 trial

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Recruiting· GSK logo

GSK·Phase 2·NCT06213506·516 enrolled

Immunity1 trial

Persistence of IPV Immunity

Completed·TTribhuvan University Teaching Hospital, Institute Of Medicine.·Phase 4·NCT03723837·502 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Inactivated polio vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inactivated polio vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inactivated polio vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: GSK

Inactivated polio vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza4 trials

Immunogenicity2 trials

Immune Response1 trial

Immunity1 trial

References

Drug Info

Quick Facts

Related News